Showing results (1841-1850 of 2,232) with videos related to

Sort By:
Pageof 224
The Journal of Pharmacology and Experimental Therapeutics|January 14, 2005
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeysJeannie R Rojas, Ronald P Taylor, Mark R Cunningham, et al.
Journal of Medicinal Chemistry|March 1, 1988
Atypical antipsychotic agents: patterns of activity in a series of 3-substituted 2-pyridinyl-1-piperazine derivativesJ S New, J P Yevich, D L Temple, et al.
Annals of Neurology|May 31, 2023
Expert Panel Curation of 113 Primary Mitochondrial Disease Genes for the Leigh Syndrome SpectrumElizabeth M McCormick, Kierstin Keller, Julie P Taylor, et al.
Ejhaem|July 18, 2022
Adult T cell leukaemia/lymphoma (ATL) in pregnancy: A UK case seriesLeila Motedayen Aval, Mary Boullier, Hermione Lyall, et al.
Nucleic Acids Research|January 10, 2003
PRINTS and its automatic supplement, prePRINTST K Attwood, P Bradley, D R Flower, et al.
Journal of Clinical Microbiology|August 1, 2002
Transmission of drug-resistant tuberculosis in Texas and MexicoTeresa N Quitugua, Barbara J Seaworth, Stephen E Weis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2004
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemiaAdam D Kennedy, Paul V Beum, Michael D Solga, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2006
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemiaMichael E Williams, John J Densmore, Andrew W Pawluczkowycz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 17, 2014
Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemiaNisar A Baig, Ronald P Taylor, Margaret A Lindorfer, et al.
Pageof 224